Johnson Investment Counsel Inc. lessened its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 8.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,556 shares of the financial services provider’s stock after selling 502 shares during the period. Johnson Investment Counsel Inc.’s holdings in iShares Biotechnology ETF were worth $705,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vontobel Holding Ltd. increased its holdings in shares of iShares Biotechnology ETF by 9.5% in the 1st quarter. Vontobel Holding Ltd. now owns 5,060 shares of the financial services provider’s stock worth $659,000 after purchasing an additional 440 shares in the last quarter. Blair William & Co. IL raised its position in iShares Biotechnology ETF by 9.7% in the first quarter. Blair William & Co. IL now owns 18,717 shares of the financial services provider’s stock worth $2,439,000 after acquiring an additional 1,659 shares during the period. NewEdge Advisors LLC boosted its stake in shares of iShares Biotechnology ETF by 11.7% during the 1st quarter. NewEdge Advisors LLC now owns 13,777 shares of the financial services provider’s stock worth $1,796,000 after acquiring an additional 1,445 shares during the last quarter. DCF Advisers LLC bought a new stake in shares of iShares Biotechnology ETF during the 1st quarter valued at $912,000. Finally, Laurel Wealth Advisors Inc. increased its stake in shares of iShares Biotechnology ETF by 22.6% in the 1st quarter. Laurel Wealth Advisors Inc. now owns 3,019 shares of the financial services provider’s stock worth $393,000 after purchasing an additional 557 shares in the last quarter. Institutional investors own 69.61% of the company’s stock.
iShares Biotechnology ETF Stock Up 0.7 %
NASDAQ IBB opened at $118.92 on Tuesday. The stock’s 50-day moving average price is $120.13 and its 200-day moving average price is $125.58. iShares Biotechnology ETF has a 52 week low of $111.83 and a 52 week high of $138.74.
iShares Biotechnology ETF Dividend Announcement
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
- Five stocks we like better than iShares Biotechnology ETF
- How Technical Indicators Can Help You Find Oversold Stocks
- Safeguard your portfolio with these three bargain stocks
- How to Invest in Grocery Stores
- Membership clubs gain leverage for the consumer rebound
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.